Dual action protection for the heart and vessels
Dual PPAR-α/γ modulation for comprehensive cardiovascular protection
Cardioxil™ binds selectively to PPAR-α receptors in hepatocytes, promoting β-oxidation of fatty acids and reducing plasma triglycerides. Simultaneously, partial PPAR-γ modulation in endothelial cells suppresses NF-κB signaling, lowering vascular inflammation without significant adipogenesis.
Enhances fatty acid oxidation in hepatocytes, reducing triglyceride levels and improving lipid metabolism
Suppresses vascular inflammation via NF-κB pathway inhibition without promoting adipogenesis
Improves endothelial function and reduces markers of vascular inflammation
Results from the Phase III ARMOR trial demonstrate significant cardiovascular risk reduction
Phase III, randomized, double-blind, placebo-controlled study in 7,200 adults with atherosclerotic cardiovascular disease (ASCVD) inadequately controlled on high-intensity statins. Patients were followed for 36 months to assess cardiovascular outcomes.
Relative risk reduction in major adverse cardiovascular events vs placebo
Significant reduction in cardiovascular mortality
Lower incidence of non-fatal myocardial infarction
Reduced risk of non-fatal stroke events
| Endpoint | Cardioxil™ + SOC (n=3,600) |
Placebo + SOC (n=3,600) |
Relative Risk Reduction |
|---|---|---|---|
| MACE (CV death, MI, stroke) | 6.5% | 9.3% | 30% |
| CV Death | 2.0% | 3.2% | 37% |
| Non-fatal MI | 3.1% | 4.8% | 35% |
| Non-fatal Stroke | 1.4% | 1.9% | 26% |
mg/dL mean reduction vs placebo at 12 weeks (P<0.001)
Mean reduction in high-sensitivity C-reactive protein (P<0.001)
Improvement in flow-mediated dilation (FMD) vs +0.9% placebo (P<0.01)
Comprehensive safety data from pooled analysis of 4,000 patients
| Adverse Event | Cardioxil™ (%) | Placebo (%) |
|---|---|---|
| Headache | 8.5 | 6.2 |
| Diarrhea | 6.7 | 5.1 |
| Nasopharyngitis | 6.3 | 4.9 |
| ALT ↑ >3× ULN | 1.9 | 1.4 |
| Edema | 1.8 | 1.6 |
50 mg tablet taken once daily, with or without food
| Adverse Event | Grade | Recommended Action |
|---|---|---|
| ALT/AST >3× ULN with symptoms | Grade 2-3 | Withhold until recovery; resume at 25 mg daily |
| Peripheral Edema | Grade 2 | Initiate diuretic; continue treatment |
| Severe Edema | Grade 3 | Withhold; resume at 25 mg after resolution |
| Creatinine ↑ >2× baseline | Grade 3 | Interrupt until ≤1.5× baseline; resume at 25 mg |
| Life-threatening AE | Grade 4 | Permanently discontinue |
We're committed to making Cardioxil™ accessible and affordable for all eligible patients
Eligible patients pay as little as $25/month with our copay savings program
Learn More →30-day free supply for newly prescribed patients to help begin treatment without delay
Request Now →Tier 2 on 68% of commercial formularies at launch. Medicare Part D coverage anticipated Q4 2025
Check Coverage →Comprehensive clinical and educational materials for healthcare providers
Complete product information including mechanism of action, clinical efficacy, safety profile, and dosing guidelines
View Brochure →
Full Phase III trial data with detailed efficacy and safety analysis from 7,200 patients
View Data →
Complete prescribing information including indications, contraindications, warnings, and precautions
View Info →